INCYte receives Japanese approval for Minjuvi lymphoma drug

SentiSense · Published · Updated

Incyte received approval in Japan for its lymphoma drug Minjuvi (pembrolizumab), despite a drop in the company's stock price.

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis